Origami B host strains carry the same trxB/gor mutations as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable pecise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami hosts in one strain background. The trxB and gor mutations are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with the plasmids carrying kanamycin or tetracycline resistance genes. These strains also include the lon and ompT deficiences of BL21, which increase protein stability. In Origami B(DE3)pLacI, the rare tRNA genes are present on the same plasmid that carries the lac repressor gene.
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
Genotype: F– ompT hsdSB (rB– mB–) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB pLacI (CamR, KanR, TetR)
|
Product information
|
|
Components
|
| 0.4 ml | 1 ml | Component
| | • | 2 × 0.2 ml | 5 × 0.2 ml | OrigamiB(DE3)pLacI Competent Cells
| | • | 2 × 2 ml | 4 × 2 ml | SOC Medium
| | • | 2 ng | 2 ng | Test Plasmid |
|
|
Guaranteed efficiency
|
Guaranteed efficiency: > 2 x 106 cfu/μg
|
|
Store and ship information
|
|
|
|
Storage
|
≤ -70°C
|
|
Ship
|
Dry Ice Only
Multiple Toxicity Values, refer to MSDS
|
|
Licence Brookhaven
|
This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.
|
